Literature DB >> 12661006

Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21).

Alain Charest1, Keara Lane, Kevin McMahon, Julie Park, Elizabeth Preisinger, Helen Conroy, David Housman.   

Abstract

The transmembrane proto-oncogene receptor tyrosine kinase (RTK) ROS is an orphan receptor that is aberrantly expressed in neoplasms of the central nervous system. Here, we report the fusion of its carboxy-terminal kinase domain to the amino-terminal portion of a protein called FIG (Fused in Glioblastoma) in a human glioblastoma multiforme (GBM). By characterizing both FIG and ROS genes in normal and in U118MG GBM cells, we determined that an intra-chromosomal homozygous deletion of 240 kilobases on 6q21 is responsible for the formation of the FIG-ROS locus. The FIG-ROS transcript is encoded by 7 FIG exons and 9 ROS-derived exons. We also demonstrate that the FIG-ROS locus encodes for an in-frame fusion protein with a constitutively active kinase activity, suggesting that FIG-ROS may act as an oncogene. This is the first example of a fusion RTK protein that results from an intra-chromosomal deletion, and it represents the first fusion RTK protein isolated from a human astrocytoma. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661006     DOI: 10.1002/gcc.10207

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  80 in total

1.  Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy.

Authors:  Bingxue Shang; Gaochuan Zhang; Yanyan Pan; Quansheng Zhou
Journal:  Cancer Microenviron       Date:  2012-05-17

Review 2.  Lung cancer as a paradigm for precision oncology in solid tumours.

Authors:  Simon Schallenberg; Sabine Merkelbach-Bruse; Reinhard Buettner
Journal:  Virchows Arch       Date:  2017-07-20       Impact factor: 4.064

3.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

Review 4.  Detecting and targetting oncogenic fusion proteins in the genomic era.

Authors:  Monika A Davare; Cristina E Tognon
Journal:  Biol Cell       Date:  2015-04-07       Impact factor: 4.458

5.  Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.

Authors:  Yoshiyuki Suehara; Maria Arcila; Lu Wang; Adnan Hasanovic; Daphne Ang; Tatsuo Ito; Yuki Kimura; Alexander Drilon; Udayan Guha; Valerie Rusch; Mark G Kris; Maureen F Zakowski; Naiyer Rizvi; Raya Khanin; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-10-10       Impact factor: 12.531

Review 6.  Current concepts on the molecular pathology of non-small cell lung carcinoma.

Authors:  Junya Fujimoto; Ignacio I Wistuba
Journal:  Semin Diagn Pathol       Date:  2014-06-12       Impact factor: 3.464

Review 7.  Oncogenic gene fusions in epithelial carcinomas.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Curr Opin Genet Dev       Date:  2009-02-21       Impact factor: 5.578

8.  Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

Authors:  Monika A Davare; Anna Saborowski; Christopher A Eide; Cristina Tognon; Rebecca L Smith; Johannes Elferich; Anupriya Agarwal; Jeffrey W Tyner; Ujwal P Shinde; Scott W Lowe; Brian J Druker
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

9.  The democratization of the oncogene.

Authors:  Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-08       Impact factor: 39.397

Review 10.  Molecular pathways: ROS1 fusion proteins in cancer.

Authors:  Kurtis D Davies; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.